Rukobia (Fostemsavir Tromethamine) Patent Expiration, LOE Window & CMS Spending

Rukobia (Fostemsavir Tromethamine) by GSK: FDA Orange Book core substance LOE 2027-11-19 (last listed 2029-07-13), 0 AB generics, $138.3M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGSK
FDA Application & PathwayN212950 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2027-11-19
Last Listed Patent or Exclusivity Date2029-07-13
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$138.3M
2024 Medicare Part D Spend$115.0M
2024 Medicaid Spend$23.2M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 17.8% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.